Advertisement


Krishnansu S. Tewari, MD, on Gynecologic Cancers: Expert Perspective on Major Data

ASCO 2026

Advertisement

Krishnansu S. Tewari, MD, of the University of California, Irvine, provides commentary on research presented in the oral abstract and rapid oral abstract sessions for gynecologic cancer, focusing on this year’s major trial data in endometrial, cervical, and ovarian cancers. 



Related Videos

Hepatobiliary Cancer

Colton Jones, MD, on GLP-1 RAs for the Prevention of HCC in High-Risk Individuals

Colton Jones, MD, of The University of Texas at San Antonio, talks about the results of a global, multicenter analysis that sought to determine the safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the primary prevention of hepatocellular carcinoma (HCC) in a pan-etiology high-risk cohort (Abstract 10522).

Breast Cancer

Erika P. Hamilton, MD, FASCO, on HER2-Positive Metastatic Breast Cancer: Maintenance Therapy Comparison

Erika P. Hamilton, MD, FASCO, of Sarah Cannon Research Institute, talks about a comparison of the efficacy and safety of tucatinib vs placebo combined with trastuzumab and pertuzumab as maintenance therapy for HER2-positive metastatic breast cancer by stratified subgroups (Abstract 1005).

Lung Cancer

Jessica J. Lin, MD, on Neladalkib in Advanced ALK-Positive NSCLC

Jessica J. Lin, MD, Mass General Brigham Cancer Institute, presents data from the ALKOVE-1 study, which is looking at the investigational ALK tyrosine kinase inhibitor (TKI) neladalkib among patients with ALK-positive non–small cell lung cancer (NSCLC); Dr. Lin discusses the first analyses of phase II TKI-pretreated patients and preliminary data in TKI-naive patients (Abstract 8503).

Lymphoma

Thomas A. Jandl, MD, PhD, on DLBCL: First-Line Odronextamab Plus Chemotherapy

Thomas A. Jandl, MD, PhD, of Stony Brook University Hospital, discusses data from part 1B of the OLYMPIA-3 trial, which showed that among patients with diffuse large B-cell lymphoma (DLBCL), the safety profile of the first-line combination of odronextamab and CHOP chemotherapy was generally manageable and preliminary efficacy was encouraging, with no meaningful differences between regimens. Additionally, combination with odronextamab did not impact the delivery of CHOP (Abstract 7009).

Prostate Cancer

Alicia K. Morgans, MD, FASCO, on Cognitive Effects of Darolutamide vs Enzalutamide

Alicia K. Morgans, MD, FASCO, of Dana-Farber Cancer Institute, discusses data from the phase II ARACOG (AFT-47) randomized clinical trial, which compared the two androgen receptor pathway inhibitors’ effects on cognitive function in patients with advanced prostate cancer (Abstract 5005).

Advertisement

Advertisement




Advertisement